EGFR and neoplasm: In this study, 11 of 17 patients showed reduction in tumor size with 4 patients meeting the criteria for clinical volumetric response; hearing response rate was observed in 4 of 13 patients.45 Unfortunately, erlotinib, an EGFR/HER-1 antagonist, has not been shown to be efficacious; one review by Plotkin et al. showed no improvement in radiographic or hearing responses in NF2 patients with progressive VS.46